Dapagliflozin Well Tolerated in COVID-19 Patients, Regardless of eGFR

FRIDAY, April 29, 2022 -- The effects of dapagliflozin are similar for hospitalized patients with COVID-19 with estimated glomerular filtration rate (eGFR)<60 and≥60 mL/min per 1.73 m2, according to a study published online April 28 in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news